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A single point mutation in the lysosomal proenzyme
receptor-inhibiting sequence near the N terminus of
mouse procathepsin L can result in glycosylation of a
normally cryptic site near its C terminus. When alanine
replaced His36, Arg38, or Tyr40, the nascent chain of the
mutant protein cotranslationally acquired a high man-
nose oligosaccharide chain at Asn268. In contrast, when
alanine replaced Ser34, Arg37, or Leu39, this second car-
bohydrate chain was not added. This alternating pat-
tern of abnormal glycosylation suggested that propep-
tide residues 36–40 normally assume an extended
conformation having the side chains of residues 36, 38,
and 40 facing in the same direction. When tyrosine con-
servatively replaced His36 or lysine replaced Arg38,
Asn268 was not glycosylated. But the procathepsin L mu-
tant having phenylalanine in place of Tyr40 was glyco-
sylated at Asn268, which indicates that the hydrogen
bond between the hydroxyl group of Tyr40 and the car-
boxylate group of Asp82 is necessary for normal folding
of the nascent proenzyme chain.
Mutation of the adjacent a2p (ERININ) helix of the
propeptide or addition of a C-terminal epitope tag se-
quence to procathepsin L also induced misfolding of the
proenzyme, as indicated by addition of the second oli-
gosaccharide chain. In contrast, the propeptide muta-
tion KAKK99–102AAAA had no effect on carbohydrate
modification even though it reduced the positive charge
of the proenzyme.
Misfolded mutant mouse procathepsin L was not effi-
ciently targeted to lysosomes on expression in human
HeLa cells, even though it acquired phosphate on man-
nose residues. The majority of the mutant protein was
secreted after undergoing modification with complex
sugars. Similarly, epitope-tagged mouse procathepsin L
was not targeted to lysosomes in homologous mouse
cells but was efficiently secreted. Since production of
mature endogenous protease was not reduced in cells
expressing the tagged protein, the tagged protein did
not compete with endogenous procathepsin L for target-
ing to lysosomes.
The lysosomal proenzyme receptor (LPR)1 is a 43-kDa inte-
gral membrane protein that binds mouse procatL at pH 5 to
microsomal membranes from mouse fibroblasts (1). A short
synthetic peptide containing a 9-residue sequence from mouse
procathepsin L (procatL) inhibits the binding of the procatL to
the LPR, but a scrambled version of this peptide does not (2). To
study the physiological effects of inhibiting pH-dependent
membrane association, we made over a dozen mutants of
mouse procatL having from one to four substitutions in the
LPR-inhibiting sequence (LIS, Lys-Ser-Thr-His-Arg-Arg-Leu-
Tyr-Gly, residues 33–41, preprocatL numbering (2)), which
begins 16 residues from the N terminus of procatL.
During expression of these mouse mutants in human HeLa
cells, we found that certain LIS residues were critical for nor-
mal glycosylation of the proenzyme. Mouse procatL contains
two potential sites (Asn221 and Asn268) for cotranslational at-
tachment of an asparagine-linked high mannose oligosaccha-
ride chain (3), but it is normally glycosylated only at Asn221 (4).
We have found that mutation of any one of several LIS resi-
dues, which are located in the N-terminal 10% of the 317-
residue procatL chain, sufficiently changes the folding of the
nascent chain during translation that it is also glycosylated at
Asn268, a normally cryptic site located in the C-terminal 20% of
the procatL chain. Secretion of a protein is often used to indi-
cate that the protein is correctly folded because grossly mis-
folded proteins are normally degraded in the endoplasmic re-
ticulum (ER) (5). Yet protein misfolding may be missed if
secretion is used as the only indicator of correct protein confor-
mation. In this study, the addition of an oligosaccharide chain
to a normally cryptic site serves as an indicator that a subtle
perturbation of the normal pathway of protein folding has
occurred.
EXPERIMENTAL PROCEDURES
Materials—Reagents used include the following: [35S]methionine
(Trans35S-label; 850–950 Ci/mmol) and [32P]orthophosphate (400–800
mCi/ml) from ICN Biomedicals, Costa Mesa, CA; Protein-A Sepharose
CL4B from Pharmacia Biotech Inc.; Dulbecco’s modified Eagle’s me-
dium, Opti-MEM, LipofectAMINE, and fetal bovine serum from Life
Technologies, Inc.; aprotinin, dithiothreitol, endo-b-N-acetylglu-
cosaminidase H (EndoH), N-glycosidase F, HEPES, pepstatin, and phe-
nylmethanesulfonyl fluoride from Boehringer Mannheim; enhanced
chemiluminescence Western blotting detection reagents and donkey
anti-rabbit and goat anti-mouse IgG conjugated to horseradish peroxi-
dase from Amersham Corp.; Immobilon-P from Millipore, Bedford, MA;
brefeldin A from Epicentre Technologies, Madison, WI; Muta-Gene in
vitro mutagenesis kit and prestained molecular mass marker proteins
from Bio-Rad; eukaryotic expression vector pSG5 from Stratagene, La
Jolla, CA; prokaryotic expression vector pET-27b and HSV-Tag mono-
clonal antibody from Novagen, Madison, WI; plasmid purification col-
umns from Qiagen, Chatsworth, CA; oligonucleotides from Lineberger
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Nucleic Acids Core Facility, University of North Carolina, Chapel Hill,
NC; restriction endonucleases, Vent polymerase, Taq polymerase, and
DNA modifying enzymes from New England Biolabs, Beverly, MA, Life
Technologies, Inc., or Promega, Madison, WI; and Sequenase V.2.0 and
nucleotides from U. S. Biochemical Corp. The cysteine protease inhib-
itor E-64, MEGA-8, and all other reagents were the highest quality
available and were obtained from either Sigma or Fisher.
Cell Culture—Mouse KNIH cells (Kirsten sarcoma virus-trans-
formed NIH 3T3 fibroblasts) were a gift of Dr. C. Scher, University of
Pennsylvania. Human HeLa and mouse NIH 3T3 cells were obtained
from the American Type Culture Collection. Rockville, MD. Cells were
grown in Dulbecco’s modified Eagle’s medium containing 4.5 g/liter
glucose, 10% fetal bovine serum, 0.005% gentamycin, 0.0025% kana-
mycin, and 200 mM glutamine.
Construction of Mutant cDNAs—Mutations were introduced into the
propeptide of mouse procatL by the method of Kunkel et al. (6) using the
Bio-Rad Muta-Gene kit according to the manufacturer’s instructions.
When possible, codons were chosen to introduce restriction sites that
facilitated identification of the mutants. Mutations were confirmed by
sequencing relevant regions of the modified single-stranded M13/mp19
phage DNA using Sequenase T7 DNA polymerase according to the
manufacturer’s instructions. The M13 replicative form was purified on
a Qiagen midi-column, digested with BamHI, and the resulting frag-
ments were resolved on an agarose gel. A 1161-base pair fragment
encoding mouse procatL was excised and extracted from the agarose
using a 0.45 mM filter (7). The fragment was ligated into dephosphoryl-
ated, BamHI-digested pSG5 vector and transformed into competent
MC1061 cells (8) using standard molecular biology techniques (9). The
plasmid pSK1.proCL.Q204 contains a mutation that converts the wild-
type Asn268 to Gln268 (4). This plasmid and procatL/pSG5 were both
digested with BstXI and SacII. The 630-base pair inserts were ex-
changed by subcloning as described above.
Construction of ProcatL-HSV Chimeric cDNA—To distinguish re-
combinant mouse procatL from the endogenous protein in mouse cells,
a 26-amino acid C-terminal epitope tag was added to the recombinant
protein. To construct the plasmid encoding this chimeric protein, the
sequence encoding procatL was first subcloned into the prokaryotic
expression vector pET-27b using the polymerase chain reaction (PCR).
The 59-oligonucleotide primer (CAGCAGCAGCATATGACTCCAAA-
ATTTGATCAAACCTTT) consisted of bases encoding an NdeI restric-
tion site followed by the bases encoding the first eight residues of the
single chain enzyme. The 39 primer (GTCGTCCTCGAGATTGACCA-
CAGGATAGCT) consisted of bases encoding an XhoI site followed by
bases complementary to the C-terminal 6 residues of procatL. The
cDNA was synthesized in a 100-ml PCR reaction mix consisting of 10 ng
of template (procatL/pSG5), 200 pM each primer, 2.5 mM deoxynucle-
otide triphosphates, 2 mM MgSO4, and 3 units of Vent DNA polymerase
in 1 3 Vent reaction buffer. This reaction mixture was subjected to 1
cycle of 94 °C for 1.0 min, 5 cycles of 94 °C for 30 s, 58 °C for 30 s, and
72 °C for 1.5 min, and 25 cycles of 94 °C for 30 s and then 72 °C for 1.5
min in a model PTC-150 thermocycler from M. J. Research, Watertown,
MA. The terminal nucleotides of the PCR product were removed with
NdeI and XhoI, and the product was ligated into the pET-27b vector
that had been previously digested with these same enzymes.
The cDNA encoding procatL and an adjacent 78-base sequence in-
cluding bases encoding the herpes simplex virus (HSV) peptide,
-SQPELAPEDPED-, and six adjacent 6 histidine residues was removed
from proL/pET-27b and subcloned back into the eukaryotic expression
vector pSG5 using PCR. The 59 primer (GCCAGATCTTCAGTGGTG-
GTGGTG) contained bases encoding a BglII site followed by bases
complementary to the stop codon and those encoding 4 histidine resi-
dues, and the 39 primer (CAGTCTTCTGTGCGTGGCCTTCCACTG-
GTGCCACTC) was a 36-base pair sequence homologous to the procatL
proregion. This PCR product and procatL/pSG5 were both digested with
BstXI and BglII, and the 740-base pair inserts were exchanged. The
insert was sequenced in denatured pSG5 using Sequenase T7 DNA
polymerase according to the manufacturer’s instructions to confirm
that no mutations were introduced by PCR during subcloning.
Eucaryotic Cell Expression—Expression plasmid DNA encoding
mouse procatL was introduced into HeLa cells or NIH 3T3 fibroblasts
using LipofectAMINE. Plasmid DNA (6 mg) and LipofectAMINE (30 ml)
were diluted individually with Opti-MEM (300 ml) and then combined
and incubated for 45 min at room temperature. Cells (60-mm dishes,
80% confluent) were washed with phosphate-buffered saline (pH 7.2,
PBS) and incubated with Opti-MEM (2.5 ml). The DNA-lipofectAMINE
complex was then added to the cells, which were incubated for 5 h
before addition of Dulbecco’s modified Eagle’s medium containing 20%
fetal bovine serum (3 ml). On day 2, this medium was replaced with cell
growth medium or serum-free medium supplemented with insulin (5
mg/ml), transferrin (5 mg/ml), and sodium selenite (5 ng/ml). On day 3,
the cells were either harvested for Western blot analysis or were radio-
labeled prior to immunoprecipitation of procatL. When specified, con-
trol cells were mock-transfected with LipofectAMINE alone.
Radiolabeling—ProcatL was radiolabeled by washing cell monolay-
ers (60-mm dishes) twice with PBS, starving for 1 h in cell starvation
medium (Dulbecco’s modified Eagle’s medium lacking methionine but
containing 4.5 g/liter glucose, 8% dialyzed fetal bovine serum, 0.005%
gentamycin, 0.0025% kanamycin, and 200 mM glutamine), and pulsing
in cell starvation medium supplemented with [35S]methionine (500
mCi/ml) for the times indicated. For experiments including chase peri-
ods, the radiolabeled medium was removed, and the cells were washed
twice with PBS and incubated with cell growth medium supplemented
with unlabeled methionine (5 mM) for the chase period indicated. When
specified, cells were incubated with brefeldin A (20 mg/ml) for 1 h prior
to the addition of medium containing the radiolabel and fresh brefeldin
A. For radiolabeling with phosphate, the cells were washed, starved for
phosphate, and then incubated for 4 h in phosphate-free medium con-
taining [32P]orthophosphate (500 mCi/ml).
Immunoprecipitation—Polyclonal rabbit antiserum was prepared as
described previously (3) against mouse procatL expressed in bacterial
cells as a fusion protein. A sample of pelleted membranes or superna-
tant was adjusted to contain 0.6% SDS, 50 mM Tris buffer (pH 9), 100
mM NaCl, and 2 mM EDTA, boiled for 3 min, and centrifuged in a
microcentrifuge for 3–5 min. In a clean tube, the supernatant was
adjusted to contain 8 mM iodoacetamide, 4% (w/v) Triton X-100, and 26
mg/ml aprotinin. Polyclonal anti-cathepsin L serum (10 ml) was added,
and the sample was rotated at 4 °C for 16 h. Antigen-antibody com-
plexes were bound to Protein A-Sepharose (40 ml of a 1:1 resin/water
slurry per 10 ml of antiserum) for 3 h at room temperature. The Sepha-
rose beads were washed four times with Tris buffer (150 mM (pH 8))
containing 150 mM NaCl, 5 mM EDTA, and 0.1% SDS. Antigen-antibody
complexes were eluted from the beads by incubation at 100 °C for 3 min
in PAGE sample buffer (3.3% SDS, 80 mM Tris (pH 7), 20% sucrose,
0.008% bromphenol blue, 17 mM EDTA) containing dithiothreitol (17
mM). Iodoacetamide (83 mM) was added to alkylate the thiol groups. The
immunoprecipitate was analyzed by SDS-PAGE on 12% polyacrylamide
gels (10) and visualized by fluorography (11). Indicated sizes of proteins
were calculated based on the relative positions of commercial radiola-
beled and prestained marker proteins.
EndoH Treatment—Following immunoprecipitation, samples to be
digested with endo-b-N-acetylglucosaminidase H (EndoH) were eluted
from the Protein A-Sepharose by boiling for 5 min in 50 mM Tris buffer
(pH 8.0, 50 ml) containing 1% SDS and 50 mM dithiothreitol. The eluate
was transferred to a clean tube. The Protein A-Sepharose was washed
with 0.3 M citrate buffer (pH 5.5, 120 ml). Part (100 ml) of this wash was
added to the eluate, EndoH (2 milliunits) was added, and the mixture
was incubated overnight at 37 °C. Proteins were precipitated with 20%
trichloroacetic acid containing yeast tRNA (25 mg/ml) for 1 h on ice and
resolved by SDS-PAGE. For EndoH treatment of nonradioactive sam-
ples (in the absence of immunoprecipitation), cells were scraped into
0.5% SDS (1.0 ml/60-mm dish), heated in a boiling water bath for 5 min,
and sonicated to disrupt DNA. Samples were split in half, diluted 1:10
with 50 mM NaH2PO4 (pH 5.5), and MEGA-8 was added to a final
concentration of 0.5%. EndoH (40 milliunits) was added to one of the
two duplicate samples, and both tubes were incubated at 37 °C for 16 h.
The proteins were then precipitated with trichloroacetic acid as de-
scribed above. For EndoH treatment of secreted proteins, cells were
incubated overnight in Dulbecco’s modified Eagle’s medium containing
insulin (5 mg/ml), transferrin (5 mg/ml), and sodium selenite (5 ng/ml) (3
ml/60-mm dish). Proteins were precipitated with trichloroacetic acid,
and the precipitate was resuspended and incubated with EndoH as
were the cell samples. Samples treated with N-glycosidase F (600
milliunits) were prepared similarly, except the buffer was 20 mM
NaH2PO4 (pH 7.2), 50 mM EDTA, 1% b-mercaptoethanol, and 0.5%
MEGA-8.
Western Blot Analysis—Cells were washed twice with PBS and har-
vested by scraping into PAGE sample buffer (0.5 ml) (10). The lysate
was sonicated for 10 s and boiled for 5 min. Secreted proteins in cell
culture medium were precipitated with 20% trichloroacetic acid con-
taining yeast tRNA (25 mg/ml) and resuspended in PAGE sample buffer
containing dithiothreitol (17 mM). Solubilized proteins were resolved on
12% polyacrylamide gels and transferred to Immobilon-P (presoaked in
0.1 M CAPS (pH 11), in 10% methanol) by using a semi-dry apparatus
(Integrated Separation Systems, Natick, MA) for 2 h at 1mA/cm2. Non-
specific binding sites were blocked for 30 min with 0.5% non-fat dry
milk (Carnation) in Tris buffer (10 mM, pH 7.5) containing NaCl (150
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mM) and Tween 20 (0.05%). Rabbit antiserum specific for mouse cathep-
sin L (diluted 1:15,000 with Tris buffer) or mouse monoclonal antiserum
specific for the HSV sequence (diluted 1:20,000 with Tris buffer) was
incubated with the blot for 2 h at 37 °C. The blots were washed and
incubated in the secondary antibody (horseradish peroxidase-conju-
gated donkey anti-rabbit or goat anti-mouse IgG diluted 1:20,000 with
Tris buffer) for 30 min at room temperature and then washed. Proteins
were detected with enhanced chemiluminescence reagent (diluted 2:3
with distilled water) and exposed to film for 1–60 min.
RESULTS
LPR-inhibiting Sequence Mutants of Mouse ProcatL Are Ex-
pressed in HeLa Cells—In preparation for a study of the phys-
iological role of the pH-dependent membrane association of
procatL, the region of the procatL cDNA that encodes the
LPR-inhibiting sequence (LIS) (2) was altered by site-specific
mutagenesis (Table I). The various forms of mouse procatL
expressed transiently in human HeLa cells were detected in
cell extracts and in the cell culture medium either by immuno-
precipitation after radiolabeling of the newly synthesized forms
or by Western blotting of the forms present under steady-state
conditions.
Expressed wild-type mouse procatL migrated as a 38-kDa
protein (Fig. 1, lanes 4–8), similar to the endogenous proen-
zyme of mouse KNIH fibroblasts (Fig. 4). This mass, which was
calculated using both commercial prestained and radiolabeled
standards, is slightly higher than the mass of 36-kDa we re-
ported previously based on standards radiolabeled in our own
lab (12).
The endogenous human procatL of HeLa cells was distin-
guished from the expressed mouse proenzyme by its molecular
mass. The human proenzyme migrated on SDS-PAGE as a
44-kDa protein that was barely detectable on most gels due to
its weak cross-reactivity with antiserum raised against SDS-
denatured mouse proenzyme (Fig. 1, lanes 1–3, arrow). The
reason for this difference in migration of mouse and human
procatL remains unclear (13).
Mutant ProcatL Is Larger than Wild-type ProcatL—The first
procatL mutant studied had 4 adjacent residues in the middle
of the LIS (His36-Arg37-Arg38-Leu39) replaced by 4 alanine res-
idues. HRRL36–39AAAA lacks 2 wild-type arginine residues
that are positively charged at pH 5–7 and a wild-type histidine
residue that is positively charged at pH 5. When this propep-
tide mutant protein was expressed in HeLa cells, a 38-kDa
form was detected that comigrated with wild-type mouse pro-
catL (Fig. 1, lane 10 versus lane 5). In addition, a 41-kDa form
was present that was absent in HeLa cells expressing the
wild-type mouse protein. The mutant protein was secreted,
although more slowly than the wild-type protein. After a 1-h
chase, the 38-kDa form of procatL was detected in the culture
medium of cells expressing the wild-type protein but was not
detectable in the culture medium of cells expressing the mu-
tant protein (Fig. 1, lanes 7 versus lane 12). After a 4-h chase,
however, three forms of the mutant protein were present in the
cell culture medium, a major 38-kDa form that comigrated with
the secreted wild-type protein, a minor 41-kDa form, and a
major 45-kDa form (Fig. 1, lane 13).
Increased Mass of the Mutant Is Due to Carbohydrate—To
determine if the larger forms of this mutant protein were due to
glycosylation of the polypeptide chain, they were treated with
EndoH, an enzyme that removes high mannose but not com-
plex oligosaccharide chains. EndoH treatment of the wild-type
forms of procatL secreted by transfected HeLa cells decreased
the mass of the 38-kDa mouse form by 2.5 kDa, as expected for
removal of a single high mannose oligosaccharide chain (Fig. 2,
lane 1 versus lane 2). Thus a complex oligosaccharide chain was
not present on this protein. Similar results (not shown) were
obtained for endogenous procatL secreted by mouse KNIH
fibroblasts.
EndoH treatment of the 38- and 41-kDa intracellular forms
of the HRRL36–39AAAA mutant produced a single protein
band at 35.5 kDa, as expected for removal of all oligosaccharide
chains (Fig. 2, lane 3 versus lane 5). Thus the difference in mass
between the 38- and 41-kDa forms is due to the presence of a
second EndoH-sensitive asparagine-linked high mannose oli-
gosaccharide chain on the 41-kDa form. In contrast, EndoH
treatment of the 45-kDa secreted form of this mutant protein
only decreased its mass to 42.5 kDa, as expected for removal of
a single high mannose oligosaccharide chain (Fig. 2, lane 4
versus lane 6). Thus the difference in mass between the 42.5-
and 35.5-kDa forms produced by EndoH treatment is due to the
presence of an EndoH-resistant complex oligosaccharide chain
on the 42.5-kDa form. The 45-kDa secreted form of the
HRRL36–39AAAA mutant of mouse procatL therefore con-
tains two asparagine-linked oligosaccharide chains, one a high
mannose chain and the other a complex oligosaccharide chain.
Mutants Are Glycosylated at Asn268, a Normally Cryptic
Site—The 38-kDa form of endogenous mouse procatL has a
single high mannose oligosaccharide chain at Asn221 (4), but
endoglycosidase treatments revealed that the 41-kDa form of
the HRRL36–39AAAA mutant protein had a second high man-
nose oligosaccharide chain. Since these proteins have only two
potential sites for the attachment of an asparagine-linked oli-
gosaccharide chain (Asn221-Asp-Thr, Asn268-Cys-Ser), the sec-
TABLE I
The LPR-inhibiting segment of mouse procathepsin L: effect of mutations on glycosylation at Asn268
Mutant protein Glycosylationat Asn268 Changed residue(s) Structural changes at pH 7
33K S T H R R L Y G41 Residues of the LPR-inhibiting sequence
1 1 1 Wild-type side chain charges at pH 7
Wild type ... W K S T H R R L Y G ... Residues of wild-type mouse procathepsin L
WKST32–35AAAA Yes ... A A A A . . . . . . ... Replaces four side chains at 32–35 by CH3
HRRL36–39AAAA Yes ... . . . . A A A A . . ... Replaces four side chains at 36–39 by CH3
S34A/R37A No ... . . A . . A . . . . ... Removes oxygen at 34 and 1 charge at 37
S34A No ... . . A . . . . . . . ... Removes oxygen at 34
R37A No ... . . . . . A . . . . ... Removes 1 charge at 37
H36A/R38A Yes ... . . . . A . A . . . ... Removes ring at 36 and 1 charge at 38
H36A Yes ... . . . . A . . . . . ... Removes imidazole ring at 36
R38A Yes ... . . . . . . A . . . ... Removes 1 charge at 38
L39A No ... . . . . . . . A . . ... Removes 3 carbons at 39
Y40A Yes ... . . . . . . . . A . ... Removes phenolic ring at 40
H36Y No ... . . . . Y . . . . . ... Replaces imidazole ring with phenol ring at 36
R38K No ... . . . . . . K . . . ... Replaces guandinium1 with CH2NH3
1 at 38
Y40F Yes ... . . . . . . . . F . ... Removes phenolic oxygen at 40
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ond oligosaccharide chain on the 41-kDa mutant proenzyme
must be attached at Asn268.
To confirm that the 41- and 45-kDa forms of mutant mouse
procatL contained an oligosaccharide chain at Asn268, this res-
idue was replaced by mutagenesis. The N268Q mutant of
mouse procatL cannot acquire a second asparagine-linked oli-
gosaccharide chain because it contains a glutamine residue in
place of Asn268 (4). The Arg38 residue of this mutant was
replaced by alanine to obtain the R38A/N268Q double mutant.
Like the HRRL36–39AAAA quadruple mutant, the R38A sin-
gle mutant secreted the 41- and 45-kDa forms of the proenzyme
(Fig. 3, lane 4). When the R38A/N268Q double mutant was
expressed in HeLa cells, however, the 41- and 45-kDa forms
were not detected either within the cells or in the cell culture
medium (Fig. 3, lanes 7 and 8). Since they were present when
Asn268 was present but were absent when Asn268 was conser-
vatively replaced by glutamine, the 43- and 45-kDa forms of
procatL must contain an oligosaccharide chain at Asn268, the
normally cryptic glycosylation site.
As expected, EndoH treatment of the intracellular forms of
the mutants R38A and R38A/N268Q generated the 35.5-kDa
form of the proenzyme, which lacks oligosaccharide (Fig. 3,
lanes 5 and 9). EndoH treatment of the secreted forms of the
R38A/N268Q mutant also generated only the 35.5-kDa form
and no larger EndoH-resistant form (Fig. 3, lane 10). But
EndoH treatment of the secreted R38A mutant also produced
the larger EndoH-resistant, complex oligosaccharide form (Fig.
3, lane 6). Thus replacing Arg38 by alanine induced addition at
Asn268 of a high mannose oligosaccharide that is later modified
to complex oligosaccharide.
When wild-type procatL is synthesized in an excessive
amount in transformed or transfected cells, a minor amount of
the doubly glycosylated 41-kDa form of the proenzyme is de-
tected (Fig. 1, lanes 4, 5, and 8). Thus cotranslational misfold-
ing and glycosylation at Asn268 might also be due in part to the
limited availability of a chaperone protein needed for normal
folding of wild-type procatL.
Glycosylation at Asn268 Does Not Correlate With Decreased
Positive Charge of the Propeptide Region—Glycosylation of the
HRRL36–39AAAA mutant at Asn268 might be due to the de-
creased positive charge of its propeptide region (residues 18–
113) resulting from replacement of two positively charged ar-
ginine residues (Arg37 and Arg38) by uncharged alanine
residues. This possibility was explored by studying the
KAKK99–102AAAA triple mutant, which has three positively
charged residues (Lys99, Lys101, and Lys102) near the C termi-
nus of the propeptide region replaced by alanines. When this
mutant was expressed in HeLa cells, the 41- and 45-kDa forms
of procatL were not detected (Fig. 4, lanes 3–7). Like recombi-
nant wild-type mouse procatL, the KAKK99–102AAAA mu-
tant protein comigrated with endogenous procatL that had
been immunoprecipitated from radiolabeled mouse KNIH fi-
broblasts (Fig. 4, lane 1). Also like the recombinant wild-type
mouse protein (Fig. 1, lane 7), the KAKK99–102AAAA mutant
FIG. 1. Expression of wild-type mouse procatL and the HRRL36–39AAAA mutant in HeLa cells. Control human HeLa cells or HeLa
cells transiently expressing either wild-type (wt) or the HRRL36–39AAAA mutant of mouse procatL were labeled with [35S]methionine for 15 min.
The radiolabel was removed and chased with unlabeled methionine for the periods specified (H, hours). Procathepsin L was immunoprecipitated
from the cells (cell) or the cell culture medium (sec) and resolved by PAGE. The vertical arrow (lane 1) points to the faint human procatL protein
band. Indicated sizes of proteins were calculated based on the relative positions of commercial radiolabeled and prestained marker proteins. Much
of the mouse proenzyme expressed in HeLa cells was secreted into the cell culture medium (lane 8), as is the endogenous enzyme synthesized by
mouse KNIH fibroblasts (26).
FIG. 2. Mutant forms of procatL acquire additional carbohy-
drate. HeLa cells transiently expressing either the wild type or the
HRRL36–39AAAA mutant of mouse procatL were labeled with [35S]me-
thionine for 1 h. The radiolabel was removed and chased with unlabeled
methionine for 4 h. Forms of procatL immunoprecipitated from the cells
(cell) or the cell culture medium (sec) were treated with EndoH as
specified and resolved by PAGE. The figure is a composite of different
exposures of a single gel.
FIG. 3. A second oligosaccharide chain is added to Asn268. HeLa
cells transiently expressing wild type, the R38A mutant, or the R38A/
N268Q mutant of mouse procatL were labeled with [35S]methionine for
30 min. The radiolabel was removed and chased with unlabeled methi-
onine for 4 h. Forms of procatL immunoprecipitated from the cells (cell)
or the cell culture medium (sec) were treated with EndoH as specified
and resolved by PAGE.
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was detected in the culture medium of transfected HeLa cells
after a 1-h chase (Fig. 4, lane 6).
We also prepared WKST32–35AAAA, a propeptide mutant
that lacks only one wild-type residue (Lys33) that is positively
charged at pH 7. When it was expressed in HeLa cells, both the
38- and 41-kDa forms of the procatL mutant were prominent
within the cells. The 38-kDa forms of the KAKK99–102AAAA
mutant and the WKST32–35AAAA mutant were present
within the cells in comparable amounts after a 30-min pulse
with [35S]methionine (Fig. 4, lane 3 versus lane 8). After a 2-h
chase, however, the 38-kDa form was present in the culture
medium of cells expressing the KAKK99–102AAAA mutant
but was still absent from the culture medium of cells express-
ing the WKST32–35AAAA mutant (Fig. 4, lane 7 versus lane
12). Thus mutation of certain residues in the propeptide region
of mouse procatL affects oligosaccharide modification of the
protein. Merely decreasing the positive charge is not sufficient
to promote glycosylation at Asn268.
ProcatL Bearing Complex Oligosaccharide Is Secreted—The
45-kDa form of the mouse procatL mutants was not detected
within HeLa cells during pulse-chase experiments. When se-
cretion was blocked by incubating the transfected cells with the
fungal metabolite brefeldin A, all three forms of the WKST32–
35AAAA mutant were detected within the cells (Fig. 5, lane 7)
but were absent in the cell culture medium (lane 8). Thus most
of the 41-kDa form of this mutant, which bears high mannose
oligosaccharide chains at both Asn221 and Asn268, appears to be
converted into the 45-kDa form by modification of one of its
high mannose chains with complex oligosaccharide. The 45-
kDa form is secreted rather than accumulating in cells.
Not All Mutants Are Glycosylated at Asn268—Other residues
in the N terminus of procatL were replaced by alanine, and the
resulting mutants were examined for their ability to undergo
glycosylation at Asn268 (Table I).
Unlike the single mutant R38A (Fig. 3), the single mutants
S34A and R37A and the corresponding double mutant S34A/
R37A were not glycosylated at Asn268 (Fig. 6). Substantial
secreted procatL was detected in the cell culture medium 1 h
after a 30-min pulse (Fig. 6, lanes 4, 9, and 14), indicating that
each of these three mutants moved through the secretory path-
way at a normal rate. After a 3-h chase two forms of the mature
enzyme were detected in cells, the 31-kDa single-chain form of
cathepsin L and the 25-kDa heavy chain of the two-chain form
(Fig. 6). Thus a portion of each of these mutants was targeted
to lysosomes and underwent normal maturation by lysosomal
proteolysis. Therefore, the hydroxyl group of Ser34 and the
guanidinium group of Arg37 are not needed for transport of
procatL to lysosomes.
In contrast, the single mutants H36A and R38A (Fig. 7, lanes
1–2 and 5–6) and the corresponding double mutant H36A/R38A
(data not shown) did undergo glycosylation at Asn268. When
expressed in HeLa cells, each of these LPR inhibiting-sequence
mutants was present within the cells in the two high mannose
forms, the 38-kDa singly glycosylated form and the 41-kDa
doubly glycosylated form. In addition, each of these mutants
was present in the cell culture medium in the doubly glycosy-
lated 41- and 45-kDa forms.
The two large hydrophobic residues in the LIS of mouse
procathepsin L, Leu39 and Tyr40, were also replaced by the
small hydrophobic residue alanine. The Y40A mutant was gly-
cosylated at Asn268 (Fig. 7, lanes 11–12), but the L39A mutant
was not efficiently glycosylated at Asn268 (Fig. 7, lanes 9–10).
Lack of a Hydroxyl Group Can Result in Glycosylation at
Asn268—When His36, Arg38, or Tyr40 was replaced by alanine,
the resulting mutant proenzyme was cotranslationally glyco-
sylated at Asn268 (Table I and Fig. 7). Each of these residues
was next individually replaced with a more conservative resi-
due. When expressed in HeLa cells, the H36Y mutant having
the hydroxyphenyl group of tyrosine in place of the imidazole
group of His36 was not efficiently glycosylated at Asn268 (Fig. 7,
lanes 3–4). Thus, unlike the small side chain of alanine, the
large flat phenolic ring of tyrosine sufficiently resembles the
large flat imidazole ring of histidine so that the nascent chain
of the H36Y mutant folds normally during translation and only
undergoes the normal glycosylation at Asn221. Similarly, the
R38K mutant having the positively charged methylammonium
group of lysine instead of the positively charged guanidinium
group of Arg38 was not appreciably glycosylated at Asn268 (Fig.
7, lanes 7–8).
In contrast, the Y40F mutant having the benzene ring of
phenylalanine in place of the hydroxybenzene ring of tyrosine
did undergo glycosylation at Asn268 (Fig. 7, lanes 13–14). This
result is surprising because wild-type mouse procatL, which is
not glycosylated at Asn268, contains just one more atom than
the Y40F proenzyme mutant, which is glycosylated at Asn268.
The crucial atom is the hydroxyl oxygen of Tyr40. These results
suggest that the hydroxyl group of Tyr40 participates in at least
one hydrogen bond that allows the nascent chain of wild-type
procathepsin L to fold during translation in a manner that
prevents glycosylation at Asn268.
FIG. 4. Mutations near the C-terminus of the procatL propep-
tide have no effect on carbohydrate modification. Mouse KNIH
cells, untransfected human HeLa cells, or HeLa cells transiently ex-
pressing either the KAKK99–102AAAA or the WKST32–35AAAA mu-
tants of mouse procatL were labeled with [35S]methionine for 30 min.
The radiolabel was removed and chased with unlabeled methionine for
the periods specified. Procathepsin L was immunoprecipitated from the
cells (cell) or the cell culture medium (sec) and resolved by PAGE. H,
hour.
FIG. 5. Mutant procatL modified with complex carbohydrate
is only detected in cells if secretion is blocked by treatment of
the cells with brefeldin A. HeLa cells transiently expressing either
wild type (wt) (lanes 1–4) or the WKST32–35AAAA mutant of mouse
procatL (lanes 5–8) were labeled with [35S]methionine for 30 min (lanes
5 and 6) or 1 h (lanes 1–4 and 7–8). The radiolabel was removed and
chased with unlabeled methionine for 3 h (lanes 5 and 6) or 4 h (lanes
1–4 and 7–8). Procathepsin L was immunoprecipitated from the cells
(cell) or the cell culture medium (sec) and resolved by PAGE. When
specified, the cells were treated with brefeldin A (BFA) for 1 h prior to
and during the pulse and chase periods. Brefeldin A blocks both secre-
tion of wild-type and mutant procatL (lanes 4 and 8) and conversion to
mature forms in lysosomes (not shown), resulting in accumulation of
the proenzyme in the cells.
Abnormal Glycosylation of Procathepsin L8812
An ERININ-Helix Mutant Is Glycosylated at Asn268—The
LIS (residues 33–41) precedes the ERININ region of procatL
(residues 44–63), a discontinuous pattern of six residues that
is conserved in several cysteine proteases (consensus: E . . .
R . . . F . . . N . . . I . . . N) and folds into an a helix (14, 15).
Structural changes in the ERININ helix might also change the
cotranslational folding of the nascent procatL chain sufficiently
to allow the normally cryptic Asn268 to undergo glycosylation.
To test this possibility, a double mutant was prepared in an
effort to retain the conformation of the ERININ a helix but
change its surface charge. The positively charged Arg48 was
replaced by a negatively charged glutamate residue, which
should increase the surface charge of the ERININ a helix by
12, and the large aromatic hydrophobe Trp52 was replaced by
the large aliphatic hydrophobe leucine, which should promote
formation of an a helix. When expressed in HeLa cells, the
resulting R48E/W52L double mutant was indeed glycosylated
at Asn268 (Fig. 7, lanes 15 and 16). Secretion of this mutant
form was reduced, however, suggesting that a significant por-
tion of the protein may be degraded in the ER.
Mutants Can Undergo Both Glycosylation at Asn268 and
Phosphorylation of Mannose Residues—To determine if the
conformational determinant recognized by the UDP-GlcNAc:
lysosomal enzyme N-acetylglucosamine 1-phosphotransferase
(16) is preserved in the propeptide mutants, three of these
mutants were expressed in HeLa cells in the presence of
[32P]orthophosphate, and the secreted forms of procatL were
examined for the presence of the radiolabel. The 38-kDa forms
of wild-type mouse procatL (Fig. 8, lane 1), the single mutants
S34A (lane 2) and R38A (lane 3), and the double mutant R38A/
N268Q (lane 4) were each labeled with [32P]phosphate. The 41-
and 45-kDa doubly glycosylated secreted forms of the R38A
mutant (lane 3) were also phosphorylated. In each case, the
radiolabel was removed by treatment with EndoH (data not
shown), indicating that the [32P]phosphate was attached to a
high mannose oligosaccharide chain.
The R38A/N268Q double mutant must be folded sufficiently
correctly for the phosphotransferase to recognize its single high
mannose oligosaccharide chain at Asn221 and to attach N-
acetylglucosamine 1-phosphate to one or more of its mannose
residues. By analogy, it is likely that the R38A single mutant is
also phosphorylated on its high mannose oligosaccharide chain
at Asn221, so that the EndoH-resistant complex oligosaccharide
chain of its 45-kDa secreted form would be located at Asn268.
Addition of a C-terminal Epitope Tag Induces Glycosylation
at Asn268 and Inhibits Lysosomal Targeting—Propeptide mu-
tants that did not acquire the second carbohydrate chain were
targeted to lysosomes as revealed by the presence of mature
forms of the enzyme in cells (Fig. 6). In contrast, mutants that
were misfolded, as revealed by addition of the second oligosac-
charide chain to at least a proportion of the expressed protein
molecules, did not reach lysosomes. However, even targeting of
wild-type mouse procatL was relatively inefficient in human
HeLa cells, making comparison of the relative targeting effi-
ciency of the various mutants difficult. To determine if the
efficiency of lysosomal targeting of the expressed mouse mu-
FIG. 6. Not all propeptide muta-
tions affect procatL folding. HeLa
cells transiently expressing the S34A,
R37A, or S34A/R37A mutants of mouse
procatL were labeled with [35S]methi-
onine for 30 min. The radiolabel was re-
moved and chased with unlabeled methi-
onine for the periods specified. H, hour.
Procathepsin L was immunoprecipitated
from the cells (cell) or the cell culture
medium (sec) and resolved by PAGE. A
longer exposure of lanes 3, 8, and 13 of the
same gel (right panel) revealed that ma-
ture forms of the three mutants are pres-
ent in cells after a 3-h chase. The mature
forms of mouse cathepsin L appear light
relative to the proprotein bands in part
because 6 of the 11 methionine residues
are removed by cleavage of the
propeptide.
FIG. 7. Most conservative mutations do not induce addition of carbohydrate to the cryptic Asn268 site. HeLa cells transiently
expressing the specified mutant forms of mouse procatL were labeled with [35S]methionine for 30 min (H36Y, R38K, L39A, Y40F, and R48E/W52L)
or 1 h (H36A, R38A, and Y40A). The radiolabel was removed and chased with unlabeled methionine for 3 h following the 30-min pulse or for 4 h
following the 1-h pulse. ProcatL was immunoprecipitated from the cells (cell) or the cell culture medium (sec) and resolved by PAGE. The figure
is a composite of different exposures of two polyacrylamide gels.
FIG. 8. Phosphotransferase recognition of procatL is not dis-
rupted by the addition of carbohydrate to Asn268. HeLa cells
transiently expressing the specified mutant forms of mouse procatL
were labeled with [32P]orthophosphate for 4 h. Procathepsin L was
immunoprecipitated from the cell culture medium and resolved by
PAGE.
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tants might be greater in homologous mouse cells than in
human HeLa cells, a mouse procatL mutant cDNA was con-
structed that encoded a 26-residue epitope tag, containing a
12-residue segment of a herpes simplex virus (HSV) protein,
attached to the C terminus of the proenzyme. The epitope-
tagged mouse proenzyme was expressed in mouse NIH fibro-
blasts, and the recombinant and endogenous forms of procatL
were visualized under steady-state conditions by consecutive
Western blotting with an antiserum that specifically recognizes
the tag on the recombinant proenzyme, followed by an anti-
serum that recognizes both the recombinant and the endoge-
nous mouse procatL.
The anti-HSV serum specific for the recombinant protein
detected 41-kDa cellular and secreted forms of procatL, larger
than the endogenous protein due to the presence of the extra
C-terminal amino acid residues (Fig. 9, panel A). In addition, a
43-kDa form of tagged procatL was detected in the transfected
cells (Fig. 9, lanes 3 and 5), and a 46-kDa form of the protein
was present in the cell culture medium (Fig. 9, lanes 4 and 6).
No mature forms of the protease were detected in cells, and no
cross-reacting protein was present in the mock-transfected con-
trol cells treated with LipofectAMINE alone (Fig. 9, lanes 1–2).
Subsequent reaction of the same blot with antiserum specific
for mouse procatL detected, in addition to the above forms of
expressed procatL, the endogenous forms expected (panel B),
38-kDa procatL and the 30-kDa single-chain and 23-kDa
heavy-chain forms of the mature protease.
Failure to detect mature forms of procatL with the HSV-
specific antiserum indicated that the expressed protein was not
being targeted to lysosomes, even in the homologous mouse
cells. To improve the chances of detecting mature forms of
cathepsin L, cells were treated with leupeptin which slows
conversion of the single-chain protein to the two-chain protein
(Fig. 9, panel B, lanes 7 and 9 versus lane 11). However, the
single-chain form of the epitope-tagged protein was still not
detectable (Fig. 9, panel A, lane 5). The 25-kDa heavy chain of
the two-chain form of cathepsin L cannot be detected by the
HSV serum because it is derived from the N terminus of the
single-chain protease and thus lacks the tag. Although it is
derived from the C terminus of the single-chain protease and
thus bears the HSV tag, the small light chain of the two-chain
form of cathepsin L was not detected by the anti-HSV serum or
the procatL antiserum because it is not retained by the 12%
polyacrylamide gel used in this experiment.
The larger forms of epitope-tagged procatL appeared similar
to the mutant forms of the proenzyme that acquire a second
oligosaccharide chain. Treatment with EndoH converted the
epitope-tagged 41- and 43-kDa cellular proteins (Fig. 10, lane
1) to a single 39-kDa protein (Fig. 10, lane 3), confirming that
the 41-kDa form possessed one and the 43-kDa form possessed
two high mannose oligosaccharide chains. The EndoH resist-
ance (Fig. 10, lane 4) and N-glycosidase F sensitivity (Fig. 10,
lane 6) of the 46-kDa secreted proenzyme indicated that this
protein had been modified with complex carbohydrate. A por-
tion of the secreted 46-kDa protein was completely EndoH-
resistant, indicating both oligosaccharide chains had acquired
complex carbohydrate and therefore should lack mannose
6-phosphate. The protein migrating as the middle band (Fig.
10, lane 4) apparently possessed one high mannose oligosac-
charide chain and one oligosaccharide chain modified with
EndoH-resistant complex sugars. As for several point muta-
tions in the propeptide, the presence of the C-terminal tag
sequence alters protein folding sufficiently to permit a signifi-
cant portion of the expressed protein to acquire the second
oligosaccharide chain at Asn268. The epitope-tagged protein is
secreted but is not sorted to lysosomes, which suggests that
even the portion lacking the second oligosaccharide chain is
misfolded.
DISCUSSION
The LPR-Inhibiting Sequence (LIS) of ProcatL—Our previ-
ous studies indicated that the mannose 6-phosphate-independ-
ent association of mouse procatL with microsomal membranes
at acidic pH requires the propeptide of the proenzyme (1). A
synthetic peptide containing the LIS (residues 33–41) inhibits
the binding of procatL to membranes in vitro, suggesting that
the LIS is involved in this membrane association (2). The
recently published three-dimensional structure of human pro-
catL (15) reveals that the LIS forms a solvent-exposed elbow
between helices a1p and a2p, which is compatible with the LIS
playing a role in the binding of procatL to the LPR. Before this
structure became available, we explored the physiological func-
tion of this mannose 6-phosphate-independent membrane as-
FIG. 9. C-terminally tagged mouse procatL is not targeted to
lysosomes in mouse fibroblasts. NIH3T3 mouse fibroblasts treated
with LipofectAMINE (NIH) or LipofectAMINE and plasmid DNA en-
coding HSV-tagged procatL (CatL-HSV) were harvested by scraping
into PAGE sample buffer. When specified, cells were treated with
leupeptin (50 mg/ml) for 24 h prior to harvesting. Proteins in the cell
culture medium were precipitated with trichloroacetic acid and resus-
pended in PAGE sample buffer. Cellular (cell) and secreted (sec) pro-
teins were resolved by PAGE and blotted to Immobilon-P. The blot was
probed with antiserum specific for the HSV tag sequence (panel A),
followed by antiserum which recognizes procatL, both the expressed
and the endogenous protein (panel B). The positions of Bio-Rad
prestained molecular mass markers (kDa) are shown on the left. On the
right, the sizes of proteins, as calculated using the marker protein sizes
reported by Bio-Rad, are indicated (kDa).
FIG. 10. C-terminally tagged mouse procatL acquires a second
oligosaccharide chain. NIH3T3 mouse fibroblasts expressing HSV-
tagged procatL (CatL-HSV) were harvested by scraping into PAGE
sample buffer. Proteins in the cell culture medium were precipitated
with trichloroacetic acid and resuspended in PAGE sample buffer.
When specified, cellular and secreted proteins were treated with EndoH
or N-glycosidase F (N-Glyc) prior to electrophoresis and blotting. Cel-
lular (cell) and secreted (sec) proteins were resolved by PAGE and
blotted to Immobilon-P. The blot was probed with antiserum specific for
the HSV tag sequence.
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sociation by examining the effect of changing one or more LIS
residues on procatL targeting. Our studies revealed that sev-
eral wild-type LIS residues are critical for normal folding and
glycosylation of procatL, which has complicated a study of the
role of the LIS in the cellular targeting of procatL.
Abnormal Glycosylation—We found that substantial glyco-
sylation of the normally cryptic Asn268 serves as an indicator of
abnormal folding of mouse procatL. Four single LIS mutants
(H36A, R38A, Y40A, Y40F) underwent substantial glycosyla-
tion at Asn268 but five others (S34A, H36Y, R37A, R38K, L39A)
did not. Alanine scanning of LIS residues 36 through 40 re-
vealed the following pattern:
Glycosylated at Asn268: H36A R38A Y40A
Not glycosylated at Asn268: R37A L39A
This alternating glycosylation pattern suggested that these
five LIS residues are folded in an extended conformation with
the side chains of residues 36, 38, and 40 pointing in one
direction and those of residues 37 and 39 pointing in the oppo-
site direction. Indeed, the three-dimensional structure of hu-
man procatL (15) reveals this to be true. Specifically, the side
chains of His36, Arg38, and Tyr40 all point in to the hydrophobic
core of the N-terminal globular domain of the procatL propep-
tide, whereas the side chains of Arg37 and Leu39 both point out
to solvent. Glycosylation of Asn268, which lies on the surface of
procatL near this domain, is blocked during the folding of
wild-type mouse procatL. Replacing His36, Arg38, or Tyr40 with
alanine changes the folding of this N-terminal globular domain
and/or its interaction with the rest of the nascent procatL
sufficiently to allow glycosylation of this normally cryptic site
at Asn268.
Conservatively replacing His36 by tyrosine or Arg38 by lysine
maintains Asn268 in its normal cryptic state. But the presence
of Tyr40 is clearly necessary to avoid cotranslational misfolding
and glycosylation at Asn268 because it cannot be replaced by
phenylalanine. This suggested that the hydroxyl group of Tyr40
forms a hydrogen bond that is necessary for normal folding of
the nascent proenzyme. Indeed, the three-dimensional struc-
ture of human procatL (15) reveals that the hydroxyl group of
Tyr40 forms a hydrogen bond to the carboxylate group of Asp82.
The absence of this single hydrogen bond evidently alters the
interaction of the N-terminal globular domain with the rest of
the nascent procatL sufficiently to allow glycosylation at
Asn268.
Phosphorylation of Mannose Residues—The enzyme that
transfers phosphate to the high mannose oligosaccharide chain
of wild-type procatL recognizes conformational determinants
on the proenzyme (17) that are apparently preserved in repre-
sentative N-terminal mutants of mouse procatL. We expected
that both high mannose oligosaccharide chains of the 41-kDa
form of a procatL mutant would be phosphorylated. Assay of
the phosphorylation of high mannose oligosaccharide chains
introduced at novel sites on cathepsin D has shown that the
phosphotransferase can modify chains attached to a variety of
sites on the proenzyme (18). Our results suggest, however, that
only one of the two oligosaccharide chains on mutant procatL
acquires phosphate. Most of the 41-kDa mutant form is trans-
formed into the 45-kDa form having one EndoH-sensitive, high
mannose oligosaccharide chain and one EndoH-resistant, com-
plex oligosaccharide chain. Since a phosphorylated high man-
nose oligosaccharide chain cannot be converted into a complex
oligosaccharide chain (19), only one of the two high mannose
oligosaccharide chains of the 41-kDa mutant form is phospho-
rylated during passage through the early Golgi compartments.
The normal glycosylation and mannose phosphorylation site at
Asn221 is on the opposite side of procatL from the cryptic
glycosylation site at Asn268 (15). Evidently the phosphotrans-
ferase cannot efficiently modify the high mannose oligosaccha-
ride chain at Asn268.
Proenzyme Secretion—The 41-kDa form of mouse procatL
mutants, which has high mannose oligosaccharide chains at
both Asn221 and Asn268, is detected to a significant extent
within the transfected HeLa cells and to a minor extent in the
cell culture medium. The majority of the secreted mutant pro-
tein is the 45-kDa form, which is produced in the trans Golgi by
conversion of the high mannose oligosaccharide at Asn268 of the
41-kDa form into an EndoH-resistant, complex oligosaccharide.
Unless its secretion is artificially blocked by brefeldin A, the
45-kDa form is rapidly secreted and is not detected within the
cells by pulse-chase assays or Western blots. Similarly, the
plasma proteins a1-proteinase inhibitor and a2-macroglobulin
are rapidly secreted from hepatocytes once they acquire com-
plex carbohydrate (20). Thus the protein misfolding detected by
addition of the second oligosaccharide chain does not signifi-
cantly alter passage through the secretory pathway, but it may
hinder targeting to lysosomes.
Lysosomal Targeting—Targeting of mouse procatL to lyso-
somes was relatively inefficient in human HeLa cells even
though the proenzyme contained mannose 6-phosphate. Ma-
ture forms of the mutants were readily detected only when a
mutant that did not alter protein folding, such as S34A or
R37A, was expressed in a large amount. After adjusting for the
number of methionine residues, 70% of newly synthesized pro-
catL was secreted, and only about 20% was processed to mature
forms. Similarly, procathepsin D targeting has been reported to
be very inefficient in heterologous cells (21). This difference in
lysosomal sorting between the two species is difficult to under-
stand if only mannose 6-phosphate receptors are involved.
In an attempt to increase the targeting efficiency of mutant
proteins, the mouse enzyme was expressed in homologous
mouse cells instead of in heterologous human cells. To distin-
guish the recombinant protease from the endogenous protein,
an epitope tag sequence was added to the C terminus of the
recombinant protein. As seen for several of our N-terminal
propeptide mutants, this modification resulted in cotransla-
tional misfolding and addition of a second oligosaccharide
chain. Similarly, we have previously observed that Asn268 is
glycosylated when the conformation of mouse procatL is altered
by insertion of a 21-residue tag sequence just before the C
terminus (4). Evidently, addition of the high mannose oligosac-
charide at Asn268 does not occur cotranslationally as the Asn268
site of procatL emerges from the ER membrane but after at
least part of the C-terminal tag sequence has emerged from the
ER membrane, when the synthesis of procatL is essentially
complete. Similarly, folding of the yeast vacuolar enzyme pro-
carboxypeptidase Y can precede glycosylation at Asn (22).
The epitope-tagged protein acquired complex carbohydrate
and was secreted. Even in homologous cells it was not effi-
ciently targeted to lysosomes, as judged by the absence of
mature forms of cathepsin L. Since that part of the tagged
protein which lacks the oligosaccharide at Asn268 also fails to
target to lysosomes, it is unlikely that this second oligosaccha-
ride chain prevents lysosomal targeting of the tagged protein.
Thus either the tag itself or a conformational change it induces
may prevent interaction with a sorting mediator.
The presence of the second oligosaccharide chain at Asn268
indicates that a mutant or tagged procatL form is misfolded.
Two observations suggest that misfolding of a mutant procatL
is sufficient to alter its targeting. First, the procatL mutants of
procatL that were glycosylated at both Asn221 and Asn268 ac-
cumulated in the culture medium more slowly than the singly
glycosylated wild-type recombinant proenzyme. After a 1-h
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chase, the proportion of mutant forms in the cell culture me-
dium was clearly less than that for the wild-type forms. But
after a 4-h chase, a substantial proportion of the mutant forms
was detected outside the cells. In contrast, grossly misfolded
proteins are not secreted but are degraded in the ER by un-
known mechanisms (5). For example, deletion of the complete
propeptide region of mouse procatL results in turnover of the
misfolded protein in the ER (23). Second, on cell lysis the
recombinant wild-type procatL remains soluble, but the recom-
binant proenzyme mutants that acquire the second oligosac-
charide chain aggregate to a significant extent (data not
shown). This result, coupled with their slower accumulation in
the cell culture medium and the addition of the second oligo-
saccharide chain, suggests that these mutant proteins remain
misfolded to a significant degree after exit from the ER
whether or not they have acquired the second carbohydrate
chain. This misfolding might interfere with their ability to
interact with a mediator of lysosomal targeting.
Expression of the tagged procatL might be expected to pro-
duce a dominant-negative phenotype characterized by exces-
sive secretion of the endogenous procatL. Lysosomal targeting
of endogenous procatL, however, was not altered when the
misfolded tagged protein was transiently expressed. Evidently
the misfolded tagged protein does not efficiently compete with
the normally folded endogenous protein for interaction with the
sorting mediator.
Roles of the LIS Residues—This study has produced four
single LIS mutants (H36A, R38A, Y40A, and Y40F) of mouse
procatL that undergo cotranslational misfolding, substantial
glycosylation at Asn268, and subsequent secretion. Four other
propeptide mutants (WKST32–35AAAA, HRRL36–39AAAA,
H36A/R38A, and R48E/W52L) also exhibit this altered pheno-
type. Clearly it is inappropriate to use any of these phenotyp-
ically altered mutant proteins to study the role of the LIS in the
lysosomal targeting of mouse procatL.
The three-dimensional structure of human procatL (15) in-
dicates that four LIS residues common to the human and
mouse proenzymes (Lys33, His36, Arg38, and Tyr40) are struc-
turally important because their side chains contribute to the
hydrophobic core of the N-terminal globular domain. Some of
them are likely to be important for the normal folding of this
domain, which is probably the earliest event in the cotransla-
tional folding of procatL. Indeed, the altered phenotype of four
mouse procatL mutants (H36A, R38A, Y40A, and Y40F) is
consistent with three of these LIS residues (His36, Arg38, and
Tyr40) being important for normal folding of this domain and
its later interactions with the rest of the proenzyme. It is well
established that a propeptide can play this chaperone role
during the folding of a nascent proenzyme chain (24, 25).
In contrast, the four intervening LIS residues of mouse pro-
catL (Ser34, Thr35, Arg37, and Leu39) have their side chains
exposed to solvent near the end of the a1p helix. Some of these
external LIS residues might be involved in the binding of the
full-length procatL to the LPR. Also, the interaction of the LIS
with the LPR may change as the protein moves from the ER,
where at pH 7 the imidazole ring of His36 should be predomi-
nantly uncharged, to the acidic prelysosome, where at pH 5 this
imidazole ring should be positively charged. Further studies of
these mutants should reveal the role of these LIS residues in
the lysosomal targeting of mouse procatL.
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